Oral fludarabine therapy in chronic lymphocytic leukemia - Increased convenience

Hematology Journal

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Boogaerts, Marc A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Oral therapy

Indexed keywords

CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FLUDARABINE PHOSPHATE; MONOCLONAL ANTIBODY; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE;

ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; EUROPE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEALTH CARE ORGANIZATION; HEART INFARCTION; HEMATOLOGY; HOME; HOSPITAL COST; HUMAN; LEUKOPENIA; LIVER CARCINOMA; LUNG INFECTION; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MONOTHERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NURSING; OPPORTUNISTIC INFECTION; PERFORMANCE; PHYSICIAN; PRURITUS; QUALITY OF LIFE; SEPTICEMIA; SKIN TOXICITY; STANDARD; THROMBOCYTOPENIA; TREATMENT PLANNING; UNITED KINGDOM; VOMITING; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; TREATMENT OUTCOME; VIDARABINE;

EID: 2942525952     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200389     Document Type: Article

References (25)

1. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-1438.
2. Li FP. Epidemiology of chronic leukemias. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (eds). Neoplastic Diseases of the Blood. Churchill Livingstone: New York, 1991; [pp 7-14].
3. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-1420.
4. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
5. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997; 15: 458-465.
6. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
7. Schering, Fludara® Product Monograph. 2003.
8. NICE. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia. Technology Appraisal Guidance - No. 29. 2001.
9. Plosker G, Figgitt D. Oral fludarabine. Drugs 2003; 63: 2317-2323.
10. Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with 'low-grade' non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574-1579.
11. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17: 18-32.
12. Klein M, Ludwig W-D, Fulle HH. 2F-ara-A pharmacokinetics including systemic availability during treatment with fludarabine phosphate given either perorally as an immediate release tablet formulation or intravenously as a solution. Onkologie 1997; 20: 137a (abstract).
13. Oscier D, Orchard JA, Culligan D, Cunningham D, Johnson S, Parker A et al. The bioavailability of oral fludarabine phosphate is unaffected by food. The Hematol J 2001; 2: 316-321.
14. Kemena A, Keating M, Plunkett W. Plasma and cellular bioavailability of oral fludarabine. Blood 1991; 78: 52a.
15. O'Rourke TJ, Burris HA, Rodriguez GI, Smith L, Etcubanas E, Melikian A. Phase I pharmacokinetic and bioavailability study of five daily intravenous and oral doses of fludarabine phosphate in patients with advanced cancer. Proc Am Soc Clin Oncol 1997; 16: 210.
16. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
17. Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258.
18. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
19. IWCLL. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110: 236-238.
20. Rossi J-F, Van Hoof A, De Bock R, Johnson S, Bron D, Foussard C et al. Oral fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia. Blood 2002; 100: 384-385.
21. Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K et al. Oral fludarabine (FMP) is highly active in patients (pts) with previously untreated chronic lymphocytic leukemia (CLL), and leads to increased STAT1 levels in vivo. Blood 2002; 100: 388.
22. Cazin B, Maloum K, Divine M, Lepretre S, Travade P, Delmer A et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts. Blood 2002; 100: 206a.
23. Koehl U, Li L, Nowak B. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc Am Assoc Cancer Res 1997; 38: 2.
24. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-2843.
25. Schering. Fludara® (fludarabine phosphate) receives marketing approval in the UK as first-line treatment for B-cell chronic lymphocytic leukemia [press release] Publisher: Schering UK. 2003; 11 February 2003.